

GARFIELD-AF Registry

Largest fully recruited multinational prospective registry in newly diagnosed atrial fibrillation (AF) patients



57,000+ AF patients enrolled within 6 weeks of diagnosis



Patients recruited from > 1,000 sites across 35 countries globally



Patients enrolled from diverse care settings including: office-based practice, various hospital departments, anticoagulation clinics and general practice



Data quality ensured with 20% data source verification under the supervision of an independent audit committee



GARFIELD-AF risk tool (freely available online) developed to help physicians with clinical decisions in AF management




Scan to learn more



Study design

- The study enrolled patients in 5 cohorts from 2010-2016
- The cohorts included patients from the VKA era (2010-2013) and the NOAC era (2013 onwards)
- Patients were followed up for 24 months from recruitment



60+ manuscripts published from the registry in international journals to date on topics including:

- Burden of Disease
- Risk Stratification
- Treatment Practice
- Therapy Persistence
- Clinical Outcomes
- Geographic Differences
- Health Economics

VKA = vitamin K antagonist; NOAC = non-VKA oral anticoagulants

REFERENCES:

Kakkar AJ et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). *Am Heart J* 2012;163(1):13-19.

af.garfieldregistry.org

AF Garfield
global anticoagulant registry in the field